Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3572MR)

This product GTTS-WQ3572MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3572MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10230MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ10932MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ3024MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ6494MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ13149MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ12241MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ15081MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ5553MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP7657
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW